Cellusion Inc.
Cellusion Inc. is a regenerative medicine startup founded by three professors in Keio university school of medicine, department of ophthalmology in January 2015. The Headquarter locates in Tokyo. Cellusion has several unique technologies including direct differentiation induction method to produce corneal endothelial substituted cells from iPS cells. There are a couple pipelines focus on cornea diseases and others. The lead program, CLS001 targeting Bullous Keratopathy, is about to start human clinical study in Japan.
